It’s notoriously tough for experimental psychiatric drugs to succeed in clinical tests. BlackThorn Therapeutics wants to show that an AI-driven, precision approach can make it easier, and today it’s added another $76 million to get the chance to prove it.
The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. One, headed for Phase 2 testing by next year, is being developed for mood or anxiety disorders. The other, for autism, could start a Phase 1 study in 2020.
Those plans… Read more »
UNDERWRITERS AND PARTNERS